Pharmapack 2024 keynote speakers discuss drug delivery and the expected wave of on-body delivery systems to deliver large volume biologics. Currently, the industry remains conservative, favoring established options such as autoinjectors.
Targeted therapies such as Interleukin and JAK inhibitors are making inroads into the Ulcerative Colitis market owing to better clinical profile and also patient convenient dosing LAS VEGAS